home / stock / sva:cc / sva:cc news

SVA:CC News and Press, Sernova Corp. From 05/24/22

Stock Information
Company Name: Sernova Corp.
Stock Symbol: SVA:CC
Market: TSXVC
Website: sernova.com
Menu
SVA:CC SVA:CC Quote SVA:CC Short SVA:CC News SVA:CC Articles SVA:CC Message Board
Get SVA:CC Alerts

News, Short Squeeze, Breakout and More Instantly...
SVA:CC - Sernova Receives Conditional Approval to Up-list to the Toronto Stock Exchange

(TheNewswire) London, Ontario – TheNewswire - May 24 , 2022 – Sernova Corp. (TSXV:SVA; ) ( OTC:SEOVF ) ; ( FSE: PSH); ( XETRA:PSH), a clinical-stage company and leader in regenerative medicine cell t...
SVA:CC - Sernova and Evotec Enter into an Exclusive Global Strategic Partnership for iPSC-Based Beta Cell Replacement Therapy to Develop and Commercialize a 'Functional Cure' for Diabetes

Partnership Leverages Sernova’s Proprietary Cell Pouch System™ with Evotec’s iPSC-Based Insulin-Producing Beta Cells Partners to Develop and Commercialize an Off-The-Shelf Cell Replacement Therapy for Treatment of Patients with Insulin-Dependent Diabetes ...

SVA:CC - Sernova Announces Abstract on Phase 1/2 Trial with Cell Pouch Selected for Oral Podium Presentation at American Diabetes Association 82nd Scientific Sessions 2022

(TheNewswire) LONDON, ONTARIO – TheNewswire - May 9, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage cell therapy therapeutics company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D...

SVA:CC - Sernova to Participate in Multiple U.S. Healthcare Investor Conferences

(TheNewswire) Sernova Engages Leading U.S.-Based Healthcare Communications Firm to Broaden Awareness of Potential ‘Functional Cure’ Technology for Type 1 Diabetes LONDON, ONTARIO – TheNewswire - May 5, 2022 – Sernova Corp. (TSXV:SVA)...
SVA:CC - Sernova Announces 2022 Annual General Meeting Results

(TheNewswire) LONDON, ONTARIO – TheNewswire - April 29, 2022 – Sernova Corp. (TSXV:SVA)(OTC:SEOVF)(FSE:PSH), a clinical stage regenerative medicine company focused on developing a potential ‘functional cure’ for type 1 diabetes (T1D) and...

SVA:CC - Data Safety Monitoring Board Recommends Continuation of Phase 1/2 Clinical Trial with Sernova's Cell Pouch System(TM) in Patients with Type-1 Diabetes

(TheNewswire) Confirms Ongoing Safety and Tolerability of Sernova’s Cell Pouch LONDON, ONTARIO – TheNewswire - March 17, 2022 – Sernova Corp. (TSXV:SVA) (OTC:SEOVF) (FSE:PSH), a clinical- stage company and leader in regenerative medicine cell the...

Previous 10 Next 10